Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis

Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis - Efficacy and safety of mitiglinide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002663

Enrollment

Registered

2009-10-24

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type-2 diabetes mellitus

Interventions

Addition of mitiglinide to the conventional antidiabetic therapy Conventional antidiabetic therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Poorly glycemic control defined as mean HbA1c levels over the last 2 months of more than 6.5 - 9.0 % and who were not receiving insulin injection therapy despite receiving treatment for > 8 weeks with conventional therapy.

Exclusion criteria

Exclusion criteria: Exclusion criteria were infectious disease, thyroid disease, liver impairment, malignant tumors, and treatment by steroids.

Design outcomes

Primary

Measure	Time frame
Improvement of glycemic control	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026